# Phase II Trial for Large ER-Negative Breast Cancers

> **NCT01869192** · PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 72 (actual)

## Conditions studied

- Malignant Neoplasm of Female Breast

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel
- **DRUG:** Capecitabine
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT01869192
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03-05
- **Primary completion:** 2009-12-18
- **Final completion:** 2010-08-21
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2019-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01869192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01869192, "Phase II Trial for Large ER-Negative Breast Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01869192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*